Strength in numbers

The war on HIV has taught some important lessons, in particular the need to evaluate clinical results in a larger context. Trials that yield unimpressive results for single drugs may nevertheless indicate good candidates for use in combination therapies. A recent example comes from a relatively new class of antiviral agent, non-nucleoside reverse transcriptase inhibitors (NNRTIs).

NNRTIs

Read the full 561 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE